COLL
Collegium Pharmaceutical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.68
−0.08%Aug 13, 2026, 11:30 UTC
Collegium Pharmaceutical entered into an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, part of a $150 million buyback program authorized in July 2025.
Source:Aug 6, 2026, 11:30 UTC
Collegium Pharmaceutical reported second quarter 2026 financial results, with quarterly net revenues of $199.9 million, up 6% year-over-year.
Aug 1, 2026, 18:12 UTC
Collegium Pharmaceutical acquired AZSTARYS, funding the deal with $350 million in cash and $300 million in debt.
Jul 20, 2026, 12:33 UTC
Collegium Pharmaceutical signed a lease for 40,288 square feet at One Lincoln in Boston's Financial District.